137 related articles for article (PubMed ID: 37030115)
1. The combination of immunotherapy and a glutamine metabolism inhibitor represents an effective therapeutic strategy for advanced and metastatic murine pancreatic adenocarcinoma.
Frejlachova A; Lencova R; Venhauerova A; Skalickova M; Uher O; Caisova V; Majer P; Tenora L; Hansen P; Chmelar J; Kopecky J; Zhuang Z; Pacak K; Zenka J
Int Immunopharmacol; 2023 May; 118():110150. PubMed ID: 37030115
[TBL] [Abstract][Full Text] [Related]
2. Mannan-BAM, TLR ligands, and anti-CD40 immunotherapy in established murine pancreatic adenocarcinoma: understanding therapeutic potentials and limitations.
Uher O; Caisova V; Padoukova L; Kvardova K; Masakova K; Lencova R; Frejlachova A; Skalickova M; Venhauerova A; Chlastakova A; Hansen P; Chmelar J; Kopecky J; Zhuang Z; Pacak K; Zenka J
Cancer Immunol Immunother; 2021 Nov; 70(11):3303-3312. PubMed ID: 33855601
[TBL] [Abstract][Full Text] [Related]
3. Identification of Immune Cell Infiltration in Murine Pheochromocytoma during Combined Mannan-BAM, TLR Ligand, and Anti-CD40 Antibody-Based Immunotherapy.
Uher O; Huynh TT; Zhu B; Horn LA; Caisova V; Hadrava Vanova K; Medina R; Wang H; Palena C; Chmelar J; Zhuang Z; Zenka J; Pacak K
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439097
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells.
Clary BM; Coveney EC; Philip R; Blazer DG; Morse M; Gilboa E; Lyerly HK
Cancer Gene Ther; 1997; 4(2):97-104. PubMed ID: 9080118
[TBL] [Abstract][Full Text] [Related]
5. Effective cancer immunotherapy based on combination of TLR agonists with stimulation of phagocytosis.
Caisová V; Uher O; Nedbalová P; Jochmanová I; Kvardová K; Masáková K; Krejčová G; Paďouková L; Chmelař J; Kopecký J; Ženka J
Int Immunopharmacol; 2018 Jun; 59():86-96. PubMed ID: 29635103
[TBL] [Abstract][Full Text] [Related]
6. Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma.
Lookian PP; Zhao D; Medina R; Wang H; Zenka J; Gilbert MR; Pacak K; Zhuang Z
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33810617
[TBL] [Abstract][Full Text] [Related]
7. Combination doxorubicin and interferon-α therapy stimulates immunogenicity of murine pancreatic cancer Panc02 cells via up-regulation of NKG2D ligands and MHC class I.
Wang WJ; Qin SH; Zhang JW; Jiang YY; Zhang JN; Zhao L
Asian Pac J Cancer Prev; 2014; 15(22):9667-72. PubMed ID: 25520086
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral immunotherapy of murine pheochromocytoma shows no age-dependent differences in its efficacy.
Uher O; Hadrava Vanova K; Lencova R; Frejlachova A; Wang H; Zhuang Z; Zenka J; Pacak K
Front Endocrinol (Lausanne); 2023; 14():1030412. PubMed ID: 37342258
[TBL] [Abstract][Full Text] [Related]
9. Glutamine mimicry suppresses tumor progression through asparagine metabolism in pancreatic ductal adenocarcinoma.
Recouvreux MV; Grenier SF; Zhang Y; Esparza E; Lambies G; Galapate CM; Maganti S; Duong-Polk K; Bhullar D; Naeem R; Scott DA; Lowy AM; Tiriac H; Commisso C
Nat Cancer; 2024 Jan; 5(1):100-113. PubMed ID: 37814011
[TBL] [Abstract][Full Text] [Related]
10. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
11. rWTC-MBTA: autologous vaccine prevents metastases via antitumor immune responses.
Ye J; Wang H; Medina R; Chakraborty S; Sun M; Valenzuela A; Sang X; Zhang Y; Uher O; Zenka J; Pacak K; Zhuang Z
J Exp Clin Cancer Res; 2023 Jul; 42(1):163. PubMed ID: 37434263
[TBL] [Abstract][Full Text] [Related]
12. Targeting pancreatic cancer metabolic dependencies through glutamine antagonism.
Encarnación-Rosado J; Sohn ASW; Biancur DE; Lin EY; Osorio-Vasquez V; Rodrick T; González-Baerga D; Zhao E; Yokoyama Y; Simeone DM; Jones DR; Parker SJ; Wild R; Kimmelman AC
Nat Cancer; 2024 Jan; 5(1):85-99. PubMed ID: 37814010
[TBL] [Abstract][Full Text] [Related]
13. Induction of Immune Response Against Metastatic Tumors via Vaccination of Mannan-BAM, TLR Ligands and Anti-CD40 Antibody (MBTA).
Medina R; Wang H; Caisová V; Cui J; Indig IH; Uher O; Ye J; Nwankwo A; Sanchez V; Wu T; Nduom E; Heiss J; Gilbert MR; Terabe M; Ho W; Zenka J; Pacak K; Zhuang Z
Adv Ther (Weinh); 2020 Sep; 3(9):. PubMed ID: 33709018
[TBL] [Abstract][Full Text] [Related]
14. Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy.
Sharma NS; Gupta VK; Garrido VT; Hadad R; Durden BC; Kesh K; Giri B; Ferrantella A; Dudeja V; Saluja A; Banerjee S
J Clin Invest; 2020 Jan; 130(1):451-465. PubMed ID: 31613799
[TBL] [Abstract][Full Text] [Related]
15. Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine.
Rong Y; Jin D; Wu W; Lou W; Wang D; Kuang T; Ni X; Qin X
BMC Cancer; 2009 Jun; 9():191. PubMed ID: 19534821
[TBL] [Abstract][Full Text] [Related]
16. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
[TBL] [Abstract][Full Text] [Related]
17. Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice.
Smith JP; Wang S; Nadella S; Jablonski SA; Weiner LM
Cancer Immunol Immunother; 2018 Feb; 67(2):195-207. PubMed ID: 29043413
[TBL] [Abstract][Full Text] [Related]
18. Adenovirus-mediated delivery of a soluble form of the VEGF receptor Flk1 delays the growth of murine and human pancreatic adenocarcinoma in mice.
Tseng JF; Farnebo FA; Kisker O; Becker CM; Kuo CJ; Folkman J; Mulligan RC
Surgery; 2002 Nov; 132(5):857-65. PubMed ID: 12464871
[TBL] [Abstract][Full Text] [Related]
19. An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma.
Jacobs C; Duewell P; Heckelsmiller K; Wei J; Bauernfeind F; Ellermeier J; Kisser U; Bauer CA; Dauer M; Eigler A; Maraskovsky E; Endres S; Schnurr M
Int J Cancer; 2011 Feb; 128(4):897-907. PubMed ID: 20473889
[TBL] [Abstract][Full Text] [Related]
20. Active immunotherapy of pancreatic cancer with tumor cells genetically engineered to secrete multiple cytokines.
Clary BM; Coveney EC; Blazer DG; Philip R; Lyerly HK
Surgery; 1996 Aug; 120(2):174-81. PubMed ID: 8751580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]